No Data
No Data
Anteris Technologies and V2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study
VClip restores mitral valve function and overcomes limitations of current technologiesBRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX: AVR), a structural heart compa
Anteris Technologies Reaches Concept Lock of First Phase of Transcatheter Edge to Edge Repair System for Heart Disease
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) and technology partner v2vmedtech, inc have reached the concept lock stage on the first phase of development for the next generation Transcatheter Edge to Edge Repair (TEER) system for mitral and tricuspid valve regurgitation.
Anteris Technologies Completes Valve-in-Valve-in-Valve Procedure With DurAVR
Structural heart company Anteris Technologies (ASX:AVR) said that it has "successfully" performed a valve-in-valve-in-valve procedure at the Karolinska University Hospital in Stockholm, Sweden, accord
Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31
Anteris Technologies (ASX:AVR) has posted its activities and quarterly cash flow for the quarter ended March 31, showing AU$10.6 million cash and net cash outflows of AU$20.2 million, according to a T
Those Who Invested in Anteris Technologies (ASX:AVR) Five Years Ago Are up 292%
Anteris Technologies Raises AU$23 Million for DurAVR Study
Anteris Technologies (ASX:AVR) raised AU$23 million through a placement of 1 million new ordinary shares at AU$23 apiece. Proceeds will primarily fund the company's preparation for the DurAVR transcat
No Data